A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea

Abstract In clinical practice, most patients with monoclonal gammopathy of undetermined significance (MGUS) undergo long-term follow-up without disease progression. There is insufficient real-world data about how closely and whether anything other than disease progression should be monitored. Herein...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ka-Won Kang, Ji Eun Song, Byung-Hyun Lee, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Chul Won Choi, Yong Park, Byung Soo Kim
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/92321d688c41476ea6b2ec870d633d6f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:92321d688c41476ea6b2ec870d633d6f
record_format	dspace
spelling	oai:doaj.org-article:92321d688c41476ea6b2ec870d633d6f2021-12-02T18:50:48ZA nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea10.1038/s41598-021-97664-y2045-2322https://doaj.org/article/92321d688c41476ea6b2ec870d633d6f2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97664-yhttps://doaj.org/toc/2045-2322Abstract In clinical practice, most patients with monoclonal gammopathy of undetermined significance (MGUS) undergo long-term follow-up without disease progression. There is insufficient real-world data about how closely and whether anything other than disease progression should be monitored. Herein, we performed a nationwide study of 470 patients with MGUS with a 10-year follow-up to determine the patterns of disease progression and other comorbidities. During the follow-up period, 158 of 470 patients with MGUS (33.62%) progressed to symptomatic monoclonal gammopathies. Most of these were multiple myeloma (134/470 patients, 28.51%), and those diagnosed within 2 years after diagnosis of MGUS was high. Approximately 30–50% of patients with MGUS had hypertension, diabetes, hyperlipidemia, and osteoarthritis at the time of diagnosis, and these comorbidities were newly developed during the follow-up period in approximately 50% of the remaining patients with MGUS. Approximately 20–40% of patients with MGUS have acute or chronic kidney failure, thyroid disorders, disc disorders, peripheral neuropathy, myocardial infarction, stroke, and heart failure during the follow-up period. Altogether, when MGUS is diagnosed, close follow-up of the possibility of progression to multiple myeloma is required, especially within 2 years after diagnosis; simultaneously, various comorbidities should be considered and monitored during the follow-up of patients with MGUS. Continuous research is needed to establish appropriate follow-up guidelines.Ka-Won KangJi Eun SongByung-Hyun LeeMin Ji JeonEun Sang YuDae Sik KimSe Ryeon LeeHwa Jung SungChul Won ChoiYong ParkByung Soo KimNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-16 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ka-Won Kang Ji Eun Song Byung-Hyun Lee Min Ji Jeon Eun Sang Yu Dae Sik Kim Se Ryeon Lee Hwa Jung Sung Chul Won Choi Yong Park Byung Soo Kim A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea
description	Abstract In clinical practice, most patients with monoclonal gammopathy of undetermined significance (MGUS) undergo long-term follow-up without disease progression. There is insufficient real-world data about how closely and whether anything other than disease progression should be monitored. Herein, we performed a nationwide study of 470 patients with MGUS with a 10-year follow-up to determine the patterns of disease progression and other comorbidities. During the follow-up period, 158 of 470 patients with MGUS (33.62%) progressed to symptomatic monoclonal gammopathies. Most of these were multiple myeloma (134/470 patients, 28.51%), and those diagnosed within 2 years after diagnosis of MGUS was high. Approximately 30–50% of patients with MGUS had hypertension, diabetes, hyperlipidemia, and osteoarthritis at the time of diagnosis, and these comorbidities were newly developed during the follow-up period in approximately 50% of the remaining patients with MGUS. Approximately 20–40% of patients with MGUS have acute or chronic kidney failure, thyroid disorders, disc disorders, peripheral neuropathy, myocardial infarction, stroke, and heart failure during the follow-up period. Altogether, when MGUS is diagnosed, close follow-up of the possibility of progression to multiple myeloma is required, especially within 2 years after diagnosis; simultaneously, various comorbidities should be considered and monitored during the follow-up of patients with MGUS. Continuous research is needed to establish appropriate follow-up guidelines.
format	article
author	Ka-Won Kang Ji Eun Song Byung-Hyun Lee Min Ji Jeon Eun Sang Yu Dae Sik Kim Se Ryeon Lee Hwa Jung Sung Chul Won Choi Yong Park Byung Soo Kim
author_facet	Ka-Won Kang Ji Eun Song Byung-Hyun Lee Min Ji Jeon Eun Sang Yu Dae Sik Kim Se Ryeon Lee Hwa Jung Sung Chul Won Choi Yong Park Byung Soo Kim
author_sort	Ka-Won Kang
title	A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea
title_short	A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea
title_full	A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea
title_fullStr	A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea
title_full_unstemmed	A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea
title_sort	nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in south korea
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/92321d688c41476ea6b2ec870d633d6f
work_keys_str_mv	AT kawonkang anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT jieunsong anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT byunghyunlee anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT minjijeon anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT eunsangyu anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT daesikkim anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT seryeonlee anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT hwajungsung anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT chulwonchoi anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT yongpark anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT byungsookim anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT kawonkang nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT jieunsong nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT byunghyunlee nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT minjijeon nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT eunsangyu nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT daesikkim nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT seryeonlee nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT hwajungsung nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT chulwonchoi nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT yongpark nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT byungsookim nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea
_version_	1718377518463975424

A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea

Ejemplares similares